Published in Gut on February 01, 2001
Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial. Inflamm Bowel Dis (2013) 1.43
Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity. Therap Adv Gastroenterol (2013) 0.87
New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut (2002) 0.84
Targeting Therapy in Pediatric Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2004) 0.79
Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig Dis Sci (2015) 0.76
Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis. BMC Gastroenterol (2017) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology (1976) 15.65
National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology (1979) 4.98
Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med (1995) 4.56
A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology (1989) 4.27
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med (1995) 2.95
A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med (1994) 2.58
Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med (1994) 2.52
Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol (1998) 2.16
Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut (1994) 2.06
Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology (1996) 1.31
Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut (1997) 1.30
Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut (1996) 1.25
Medical management of Crohn's disease. Hepatogastroenterology (1990) 1.00
Medical therapy of inflammatory bowel disease. Digestion (1998) 0.93
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology (1998) 5.02
Dysbiosis in inflammatory bowel disease. Gut (2004) 5.01
Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med (1994) 4.76
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut (2008) 4.41
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med (1991) 4.09
European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology (1984) 4.09
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 4.08
Isolation and characterization of adenovirus messenger ribonucleic acid in productive infection. J Virol (1972) 3.83
Selective assay of monomeric and filamentous actin in cell extracts, using inhibition of deoxyribonuclease I. Cell (1978) 3.74
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut (2000) 3.69
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut (2009) 3.50
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut (2008) 3.14
The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol (1998) 3.04
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 3.00
RNA synthesis and processing in adenovirus-infected cells. Cold Spring Harb Symp Quant Biol (1975) 2.82
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 2.81
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology (1999) 2.80
A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med (1989) 2.71
Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut (1984) 2.70
A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med (1994) 2.58
A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med (1998) 2.54
Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med (1994) 2.52
Isolation of mRNA from KB-cells by affinity chromatography on polyuridylic acid covalently linked to Sepharose. Eur J Biochem (1972) 2.48
Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology (1995) 2.47
Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV. Gastroenterology (1991) 2.42
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet (1999) 2.29
Current status of genetics research in inflammatory bowel disease. Genes Immun (2005) 2.29
Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun (2001) 2.28
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther (2015) 2.25
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology (1997) 2.18
An in-depth study of Crohn's disease in two French families. Gastroenterology (1993) 2.15
European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis (2008) 2.14
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology (1996) 2.08
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol (2001) 2.06
Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol (1998) 2.03
Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol (1997) 2.02
Reorganization of actin in platelets stimulated by thrombin as measured by the DNase I inhibition assay. Proc Natl Acad Sci U S A (1979) 2.02
Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. N Engl J Med (1985) 1.98
Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression. Aliment Pharmacol Ther (2014) 1.96
Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer. Gut (1980) 1.95
[Quality assurance in endoprosthetics]. Z Orthop Ihre Grenzgeb (1998) 1.95
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Dysbiosis as a prerequisite for IBD. Gut (2004) 1.93
Common genetic influences on BMI and age at menarche. Hum Biol (1995) 1.93
Analysis of clinical specimens by hybridisation with probe containing repetitive DNA from Plasmodium falciparum. A novel approach to malaria diagnosis. Lancet (1984) 1.92
Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol (1996) 1.89
Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med (1992) 1.88
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther (2004) 1.87
Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology (1997) 1.84
Incidence of inflammatory bowel disease in northern France (1988-1990). Gut (1994) 1.81
On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial. Aliment Pharmacol Ther (1999) 1.80
In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology (1998) 1.74
Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol (1999) 1.74
Identification of the in vitro translation products of adenovirus mRNA by immunoprecipitation. J Virol (1975) 1.74
Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology (1996) 1.73
Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) Gastroenterology (1993) 1.71
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther (2005) 1.70
Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol (1997) 1.69
Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol (2000) 1.69
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology (1997) 1.69
Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology (1999) 1.68
Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology (1986) 1.67
Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol (2002) 1.66
Treatment of diversion colitis by short-chain fatty acids. Prospective and double-blind study. Dis Colon Rectum (1991) 1.65
The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther (2004) 1.64
Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease? Proc Natl Acad Sci U S A (2001) 1.63
Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies. Gut (1986) 1.63
Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology (1984) 1.62
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther (2004) 1.62
Genetically related Escherichia coli strains associated with Crohn's disease. Gut (2001) 1.61
Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol (1998) 1.60
Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc (1999) 1.59
Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. Br Med J (Clin Res Ed) (1988) 1.59
Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology (1996) 1.58
Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liège county of Belgium. Gut (1994) 1.57
High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol (1998) 1.57
Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. Eur J Nucl Med (1998) 1.56
Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology (1999) 1.54
Perioperative endoscopy of the whole small bowel in Crohn's disease. Gut (1993) 1.54